DE50103881D1 - Monoclonal antibody, mbAb 1E8, which is specific for the first two N-terminal amino acids of amyloid beta peptides and its use for the detection of amyloid beta peptides and / or sAPPa - Google Patents

Monoclonal antibody, mbAb 1E8, which is specific for the first two N-terminal amino acids of amyloid beta peptides and its use for the detection of amyloid beta peptides and / or sAPPa

Info

Publication number
DE50103881D1
DE50103881D1 DE50103881T DE50103881T DE50103881D1 DE 50103881 D1 DE50103881 D1 DE 50103881D1 DE 50103881 T DE50103881 T DE 50103881T DE 50103881 T DE50103881 T DE 50103881T DE 50103881 D1 DE50103881 D1 DE 50103881D1
Authority
DE
Germany
Prior art keywords
amyloid beta
beta peptides
monoclonal antibody
mbab
sappa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE50103881T
Other languages
German (de)
Inventor
Dr Wiltfang
Thomas Dyrks
Dr Moenning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE50103881D1 publication Critical patent/DE50103881D1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G01N33/561—Immunoelectrophoresis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A monoclonal antibody designated mAb1E8 deposited as DSMZ number ACC2458, is new. <??>An Independent claim is also included for an antibody mAb1E8 radioactively marked.
DE50103881T 2001-06-12 2001-06-12 Monoclonal antibody, mbAb 1E8, which is specific for the first two N-terminal amino acids of amyloid beta peptides and its use for the detection of amyloid beta peptides and / or sAPPa Expired - Fee Related DE50103881D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01114192A EP1270592B1 (en) 2001-06-12 2001-06-12 Monoclonal antibody, mAb 1E8, which is specific for the first 2 amino-terminal amino acids of beta-amyloid peptides and its use in the detection of beta-amyloid peptides or sAPPs

Publications (1)

Publication Number Publication Date
DE50103881D1 true DE50103881D1 (en) 2004-11-04

Family

ID=8177701

Family Applications (1)

Application Number Title Priority Date Filing Date
DE50103881T Expired - Fee Related DE50103881D1 (en) 2001-06-12 2001-06-12 Monoclonal antibody, mbAb 1E8, which is specific for the first two N-terminal amino acids of amyloid beta peptides and its use for the detection of amyloid beta peptides and / or sAPPa

Country Status (6)

Country Link
US (1) US6849416B2 (en)
EP (1) EP1270592B1 (en)
JP (1) JP2003012700A (en)
AT (1) ATE277952T1 (en)
DE (1) DE50103881D1 (en)
ES (1) ES2228697T3 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
EP1469312A1 (en) * 2003-04-18 2004-10-20 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis of Alzheimer's disease
EP1480041A1 (en) * 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
US20080026995A1 (en) * 2003-07-25 2008-01-31 Ac Immune Sa Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
US20080199879A1 (en) * 2004-10-28 2008-08-21 Sanko Junyaku Co., Ltd. Method of Assaying Alzheimer's Disease and Diagnostic Reagent
CA2631195C (en) 2005-11-30 2016-04-05 Abbott Laboratories Monoclonal antibodies against amyloid beta protein and uses thereof
KR20080090408A (en) 2005-11-30 2008-10-08 아보트 러보러터리즈 Anti-abeta; globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
RS53291B (en) * 2005-12-12 2014-08-29 Ac Immune S.A. A beta 1-42 specific monoclonal antibodies with therapeutic properties
EP1811304A1 (en) * 2006-01-18 2007-07-25 Friedrich-Alexander-Universität Erlangen-Nürnberg Large Aß-peptide binding particles (LAPS) in diagnosis and therapy of Alzheimer's dementia
TWI551607B (en) 2006-07-14 2016-10-01 Ａｃ免疫公司 Humanized antibody
FR2904113A1 (en) * 2006-07-21 2008-01-25 Exonhit Therapeutics S A Sa METHODS AND TOOLS FOR THERAPY OF NEURODEGENERATIVE PATHOLOGIES
CA2669848A1 (en) * 2006-11-17 2008-05-22 Friedrich-Alexander-Universitaet Erlangen-Nuernberg Method of differentially diagnosing dementias
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CN101820911B (en) * 2007-06-12 2015-05-06 Ac免疫有限公司 Humanized antibodies to amyloid beta
SG10201505369QA (en) * 2007-10-05 2015-08-28 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
WO2010006318A2 (en) * 2008-07-11 2010-01-14 Life Technologies Corporation Electrophoretically enhanced detection of analytes on a solid support
WO2010046332A1 (en) * 2008-10-20 2010-04-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for detecting soluble amyloid precursor protein (app) alpha and/or soluble app beta
CN102192985A (en) * 2010-03-18 2011-09-21 上海依科赛生物制品有限公司 Human beta-amyloid kit
DE102010014684A1 (en) 2010-04-09 2011-10-13 Universität Duisburg-Essen New approaches to Alzheimer's diagnosis
MX360403B (en) 2010-04-15 2018-10-31 Abbvie Inc Amyloid-beta binding proteins.
CN103179981B (en) 2010-07-30 2017-02-08 Ac免疫有限公司 Safe and functional humanized antibodies
EP3527220A1 (en) 2010-08-12 2019-08-21 AC Immune S.A. Vaccine engineering
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
AR083561A1 (en) 2010-10-26 2013-03-06 Ac Immune Sa PREPARATION OF AN ANTIGENIC CONSTRUCTION
US9222947B2 (en) 2012-02-03 2015-12-29 Shionogi & Co., Ltd. Anti-sAPPβ antibody
EP2989446B1 (en) * 2013-04-24 2018-10-03 Euroimmun Medizinische Labordiagnostika AG Method of automated evaluation of incubated immunoblot strips
NL2022504B1 (en) 2019-02-04 2020-08-19 Elstar Dynamics Patents B V Improved optical modulator
US12007660B2 (en) 2021-06-24 2024-06-11 Elstar Dynamics Patents B.V. Light modulator, substrate comprising electrodes and smart glazing

Also Published As

Publication number Publication date
EP1270592A1 (en) 2003-01-02
ES2228697T3 (en) 2005-04-16
US6849416B2 (en) 2005-02-01
EP1270592B1 (en) 2004-09-29
US20030166019A1 (en) 2003-09-04
JP2003012700A (en) 2003-01-15
ATE277952T1 (en) 2004-10-15

Similar Documents

Publication Publication Date Title
DE50103881D1 (en) Monoclonal antibody, mbAb 1E8, which is specific for the first two N-terminal amino acids of amyloid beta peptides and its use for the detection of amyloid beta peptides and / or sAPPa
EA200300637A1 (en) HUMANIZED ANTIBODIES, RECOGNIZING BETA AMYLOID PEPTIDE
EA200401170A1 (en) HUMANIZED ANTIBODIES, RECOGNIZING BETA AMYLOID PEPTIDE
PT809656E (en) SPECIFIC MONOCLONAL ANTIBODIES OF BETA-A4 PEPTIDE
ATE177754T1 (en) FRAGMENTS OF PRION PROTEINS.
EA200501891A1 (en) HUMANIZED ANTIBODIES, RECOGNIZING BETA AMYLOID PEPTIDE
WO2003039467A3 (en) Monoclonal antibodies specific for beta-amyloid.
EA199700087A1 (en) METHOD OF INHIBITING KATEPSIN K
NO331148B1 (en) Use of a monoclonal or polyclonal antibody, as well as methods and kits for in vitro diagnosis.
ES552534A0 (en) A METHOD FOR OBTAINING A COMPLEMENTARY POLYPEPTIDE OF AT LEAST ONE PORTION OF AN ORIGINAL PEPTIDE OR PROTEIN.
IT1271461B (en) ANTI-CD3 / ANTI-EGFR MONOCLONAL ANTI-BODY ANTIBODY, PROCESS FOR PRODUCTION AND ITS USE.
ITMI951764A0 (en) ENGINEERED PEPTIDE SYNTHETASES AND THEIR USE FOR THE NON-RIBOSOME PRODUCTION OF PEPTIDES
DE69531958D1 (en) (1-3) -BETA-D-GLUUCON-BINDING PROTEIN, ANTIBODY DETECTING THIS PROTEIN AND USE OF THE PROTEIN AND ANTIBODY
NO976094D0 (en) New peptides derived from human heat shock protein 60 for the treatment of diabetes, method and kit
DE69319909D1 (en) Peptides for the diagnosis and immunization against T. Cruzi infections
DE69434662D1 (en) Coding of a gene for aureobasidin sensitivity regulating protein
DE69837811D1 (en) HUMAN LYSOPHOSPHACIDIC ACID RECEPTOR AND ITS USE
PT840620E (en) IL-8 ANTAGONISTS FOR ASTHMA TREATMENT
DE69529272D1 (en) MONOCLONAL ANTIBODY AGAINST THE HUMANE Mx-PROTEIN MxA
PT1379650E (en) PREFERRED SEGMENTS OF NTP NEURONAL CHAIN PROTEIN AND PROCEDURES FOR THEIR USE.
EP1645285A3 (en) Therapeutical use of anti-mag antibody for the treatment of ischemic stroke
PT723552E (en) OLIGOPEPTIDES DERIVED FROM REAGENT PROTEIN FRAGMENTS
DE59608073D1 (en) ANTIBODIES AGAINST A FUSION POLYPEPTIDE HAVING A HISTIDINE PART
ATE230761T1 (en) MONOCLONAL ANTIBODIES AGAINST A COMPLEX OF HUMAN ACT AND A SERINE PROTEASE
DK0994187T3 (en) Renin-active substance comprising human prorenin and antibodies against the prorenin profragment

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee